Press Release

Abliva AB (publ), 556595-6538
12 August 2020 11:30:00 CEST - Lund, Sweden

Abliva arranges Mitochondria Day on 16 September 2020

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the day is to increase understanding of the enormous medical need within primary mitochondrial diseases, treatments under development, as well as the growing interest in investments in the area.

We begin by taking a closer look at what it's like to be a patient and a relative, and how health care experts work. Furthermore, representatives from the company will present Abliva's program in drug development, followed by exciting insights into clinical development and clinical studies with the help of our network of international experts. We conclude the day with a discussion on the views on, and conditions for, investments in projects for the development of medicines for rare diseases.

The program is designed to be of interest both for those who have a professional interest – in health care, research, or the media – as well as for patients, relatives, and the interested public. The Mitochondria Day is part of The World Mitochondrial Disease Week, which runs from 13 to 19 September. https://mitochondrialdiseaseweek.org.

The event is virtual, requires no pre-registration, and can be followed via link (to be sent out shortly). The recording will also be posted afterwards on Abliva's website, www.abliva.com. Some of the presentations/interviews will be held in Swedish and some in English. During the event you can ask questions via ir@abliva.com.

A warm welcome on 16 September!

For more information, please contact:

Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

For news subscription, please visit: http://abliva.com/press-releases/subscription-page/
Follow us on LinkedIn: https://www.linkedin.com/company/abliva
Subscribe to our YouTube channel: https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg

Press Release

Abliva AB (publ), 556595-6538
12 August 2020 11:30:00 CEST - Lund, Sweden

About primary mitochondrial diseases

Primary mitochondrial diseases are metabolic diseases that affect the ability of cells to convert energy. The disorders can manifest differently depending on the organs affected by the genetic defects and are viewed as clinical syndromes. An estimated 125 in every 1,000,000 people suffer from a primary mitochondrial disease. Primary mitochondrial diseases often present in early childhood and lead to severe symptoms, such as mental retardation, heart failure and rhythm disturbances, dementia, movement disorders, stroke-like episodes, deafness, blindness, limited mobility of the eyes, vomiting, and seizures.

Abliva – Delivering mitochondrial health

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD+ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Abliva arranges Mitochondria Day on 16 September 2020